Pyoderma gangrenosum: a review with special emphasis on Latin America literature
| Autor: | Milton José Max Rodríguez-Zúñiga, Michael S. Heath, João Renato Vianna Gontijo, Alex G. Ortega-Loayza |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Latin Americans Cyclophosphamide Review Dermatology Disease Inflammatory bowel diseases Dapsone Diagnosis Differential 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Pyoderma gangrenosum Prevalence medicine Humans business.industry Inflammatory Bowel Diseases Skin ulcer medicine.disease Latin America RL1-803 030220 oncology & carcinogenesis Cohort medicine.symptom business medicine.drug |
| Zdroj: | Anais Brasileiros de Dermatologia, Vol 94, Iss 6, Pp 729-743 (2020) Anais Brasileiros de Dermatologia Anais Brasileiros de Dermatologia v.94 n.6 2019 Anais brasileiros de dermatologia Sociedade Brasileira de Dermatologia (SBD) instacron:SBD |
| ISSN: | 0365-0596 |
| DOI: | 10.1016/j.abd.2019.06.001 |
| Popis: | Pyoderma gangrenosum is a neutrophilic dermatosis characterized by chronic ulcers due to an abnormal immune response. Despite the existence of diagnostic criteria, there is no gold standard for diagnosis or treatment. In Latin America, recognizing and treating pyoderma gangrenosum is even more challenging since skin and soft tissue bacterial and non-bacterial infections are common mimickers. Therefore, this review aims to characterize reported cases of pyoderma gangrenosum in this region in order to assist in the assessment and management of this condition. Brazil, Mexico, Argentina, and Chile are the countries in Latin America that have reported the largest cohort of patients with this disease. The most frequent clinical presentation is the ulcerative form and the most frequently associated conditions are inflammatory bowel diseases, inflammatory arthropaties, and hematologic malignancies. The most common treatment modalities include systemic corticosteroids and cyclosporine. Other reported treatments are methotrexate, dapsone, and cyclophosphamide. Finally, the use of biological therapy is still limited in this region. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|